Phase II study on feasibility of sentinel lymph node biopsy for ycN0 patients treated with primary chemotherapy in cT1-3N1M0 breast cancer

Phase II study on feasibility of sentinel lymph node biopsy for ycN0 patients treated with primary chemotherapy in cT1-3N1M0 breast cancer - SHARE study

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000030558

Enrollment

240

Registered

2018-02-01

Start date

2018-02-01

Completion date

Unknown

Last updated

2025-07-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer

Interventions

sentinel node biopsy

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria:

Exclusion criteria

Exclusion criteria: 1) Non-invasive cancer, or T4 and/or M1 breast cancer. 2) Clinical N0 or N2 and more metastases. 3) Women with pregnancy or breast-feeding. 4) Synchronous bilateral breast cancer 5) Cases with other invasive disease during treatment.

Design outcomes

Primary

Measure	Time frame
false negative rate of sentinel node biopsy	—

Countries

Japan

Contacts

Public ContactSATOMI YANA

Japanese Society for Sentinel Node Navigation Surgery Office

yanas@z7.keio.jp03-3353-6440

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Feb 9, 2026